1. Home
  2. MXCT vs JYNT Comparison

MXCT vs JYNT Comparison

Compare MXCT & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MXCT
  • JYNT
  • Stock Information
  • Founded
  • MXCT 1999
  • JYNT 2010
  • Country
  • MXCT United States
  • JYNT United States
  • Employees
  • MXCT N/A
  • JYNT N/A
  • Industry
  • MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • JYNT Multi-Sector Companies
  • Sector
  • MXCT Health Care
  • JYNT Miscellaneous
  • Exchange
  • MXCT Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • MXCT 148.2M
  • JYNT 170.3M
  • IPO Year
  • MXCT 2021
  • JYNT 2014
  • Fundamental
  • Price
  • MXCT $1.45
  • JYNT $9.98
  • Analyst Decision
  • MXCT Buy
  • JYNT Strong Buy
  • Analyst Count
  • MXCT 4
  • JYNT 3
  • Target Price
  • MXCT $7.50
  • JYNT $16.33
  • AVG Volume (30 Days)
  • MXCT 797.5K
  • JYNT 88.4K
  • Earning Date
  • MXCT 11-05-2025
  • JYNT 11-06-2025
  • Dividend Yield
  • MXCT N/A
  • JYNT N/A
  • EPS Growth
  • MXCT N/A
  • JYNT N/A
  • EPS
  • MXCT N/A
  • JYNT N/A
  • Revenue
  • MXCT $35,754,000.00
  • JYNT $53,449,713.00
  • Revenue This Year
  • MXCT N/A
  • JYNT $8.06
  • Revenue Next Year
  • MXCT $14.79
  • JYNT $11.18
  • P/E Ratio
  • MXCT N/A
  • JYNT N/A
  • Revenue Growth
  • MXCT N/A
  • JYNT 277.36
  • 52 Week Low
  • MXCT $1.26
  • JYNT $9.58
  • 52 Week High
  • MXCT $5.20
  • JYNT $13.47
  • Technical
  • Relative Strength Index (RSI)
  • MXCT 43.25
  • JYNT 30.53
  • Support Level
  • MXCT $1.39
  • JYNT $10.47
  • Resistance Level
  • MXCT $1.49
  • JYNT $10.74
  • Average True Range (ATR)
  • MXCT 0.06
  • JYNT 0.22
  • MACD
  • MXCT 0.04
  • JYNT -0.05
  • Stochastic Oscillator
  • MXCT 76.47
  • JYNT 8.33

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: